New Multi-Organ-Chip project towards vaccine & drug candidate testing for Tuberculosis
New Multi-Organ-Chip project towards vaccine & drug candidate testing for Tuberculosis
Berlin, Germany, November 7th, 2022
TissUse will receive funding from the Bill & Melinda Gates Foundation to develop a human preclinical lung-liver-lymph node co-culture on a HUMIMIC Chip infectable with Mycobacterium tuberculosis. This collaboration will contribute to the development of Tuberculosis vaccine candidates and treatment modalities.
TissUse announced today that it has received funding from the Bill & Melinda Gates Foundation for a 3-year project. The joint research activities have the goal to develop a vascularized microphysiological system interconnecting human lung, liver and lymph node organoids capable of screening Tuberculosis vaccine candidates and treatment modalities.
“We are pleased to collaborate in this project with the TuBerculosis Vaccine Initiative (TBVI) as a coordinator and the Centre National de Recherche Scientifique (CNRS) as a?scientific partner.” – Prof. Dr. Uwe Marx, CSO of TissUse.
The microphysiological model will support tissue homeostasis and will be monitorable for treatment efficacy over weeks. After airborne infection with Mycobacterium Tuberculosis, the new model system aims to show the disease-specific phenotype of “frustrated” phagocytosis, air-blood barrier damage, activated lymph node tissue and granuloma formation and maintenance. The disease model will then be used to test screening of TB vaccine candidates.
“We are excited to be able to contribute with this project to the development of new vaccines and future treatments for Tuberculosis and would like to thank the Bill & Melinda Gates Foundation for supporting our vision and funding this project.” – Dr. Reyk Horland, CEO of TissUse.
?
About TissUse
TissUse is a Berlin, Germany-based, biotechnology company, which has developed a unique “Multi-Organ-Chip” platform that provides unparalleled preclinical insight on a systemic level using human tissues. This enabling technology platform consists of a miniaturized construct that closely simulates the activity of multiple human organs in their true physiological context. TissUse’s Multi-Organ-Chips provide a new approach to predict, for example, toxicity, ADME profiles and efficacy in vitro, reducing and replacing laboratory animal testing and streamlining human clinical trials.
TissUse’s Multi-Organ-Chips have been utilized in a large variety of applications including drug development, cosmetics, food and nutrition and consumer products since 2012.
Press contact TissUse GmbH:
Christine Schwenk, Business Development Manager
TissUse GmbH, Oudenarder Str. 16, 13347 Berlin, Germany
Tel.: 0049-30 513-026-400 Fax: 0049-30-513-026-401
E-mail: [email protected]
Web: www.tissuse.com